Home ›
Leukemia Trials ›
NCT05305859
Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML
The purpose of this study is to evaluate the safety and efficacy of Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of relapsed and/or refractory AML
Trial Details
NCT ID NCT05305859
Phase PHASE2
Sponsor The First Affiliated Hospital of Xiamen University
Status RECRUITING
Cancer Type Leukemia
Interventions venetoclax combining chidamide and azacitidine (VCA)
Locations (sample) Xiamen, Fujian, China|24.47979,118.08187
Key Eligibility Criteria
Relapsed and refractory patients with acute myeloid leukemia via morphology and immunology Life expectancy ≥ 3 months Adequate laboratory parameters during the screening period as evidenced by the following: Creatinine clearance≥30 mL/min and serum Creatinine ≤ 160µmol/L
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Leukemia Trials on Trialify →